Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale
Tweet Send to a Friend
Canaccord Genuity reiterated a Buy rating on Allergen (NYSE: AGN), and raised the price target to $396.00 (from $352.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
